

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: Amniotic Membrane and Amniotic Fluid is addressed separately in medical policy 00458.

Note: Peripheral Nerve Injury Repair Using Synthetic Conduits or Processed Nerve Allografts is addressed separately in medical policy 00926

Note: This MP is not applicable to injection laryngoplasty for the treatment of vocal fold paralysis or paresis.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider breast reconstructive surgery using allogeneic acellular dermal matrix products* (including each of the following: AlloDerm[®]‡, Cortiva[®]‡ [AlloMax[™]][‡], DermACELL[™]‡, DermaMatrix[™]‡, FlexHD[®]‡, FlexHD[®]‡ Pliable[™]‡, SimpliDerm[®]‡, Strattice[™])[‡] to be **eligible for coverage**.**

- When there is insufficient tissue expander or implant coverage by the pectoralis major muscle and additional coverage is required; **OR**
- When there are viable but compromised or thin postmastectomy skin flaps that are at risk of dehiscence or necrosis; **OR**
- The inframammary fold and lateral mammary folds have been undermined during mastectomy and reestablishment of these landmarks is needed.

Based on review of available data, the Company may consider treatment of diabetic foot ulcers using the following tissue-engineered skin substitutes to be **eligible for coverage**** when **ALL** of the following criteria are met:

- For chronic, noninfected, full-thickness diabetic foot ulcers; **AND**
- Lack of adequate response following a 1-month period of conventional ulcer therapy; **AND**
- One of the following substitutes/ quantities will be used:

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- AlloPatch^{®†} *- up to 6 weekly applications; if ulcer persists after initial applications and achieved greater than 50% wound closure, can approve up to 6 additional weekly applications; **OR**
- Apligraf^{®†} **- up to 5 applications over 5 weeks; **OR**
- Dermagraft^{®†} ** - up to 8 applications over 12 weeks; **OR**
- Integra^{®†} Omnigraft Dermal Regeneration Matrix (also known as Omnigraft) and Integra Flowable Wound Matrix- up to 2 applications total; **OR**
- PriMatrix^{™†}- limited to one initial application and 2 additional weekly applications (up to a maximum of 3 applications total in 12 weeks) when evidence of wound healing is present (e.g., signs of epithelialization and reduction in ulcer size); **OR**
- mVASC^{®†} - up to 6 weekly applications; if ulcer persists after initial applications and achieved greater than 50% wound closure, can approve up to 6 additional weekly applications; **OR**
- TheraSkin^{®†}- up to 6 weekly applications; if ulcer persists after initial applications and achieved greater than 50% wound closure, can approve up to 6 additional weekly applications; **OR**
- Kerecis^{®†} Omega3 -up to 6 weekly applications; if ulcer persists after initial applications and achieved greater than 50% wound closure, can approve up to 6 additional weekly applications.

Based on review of available data, the Company may consider treatment of lower-extremity skin ulcers due to venous insufficiency using the following tissue-engineered skin substitutes to be **eligible for coverage**** when **ALL** of the following criteria are met:

- For chronic, noninfected, partial- or full-thickness lower-extremity skin ulcers due to venous insufficiency; **AND**
- Lack of adequate response following a 1-month period of conventional ulcer therapy; **AND**
- One of the following substitutes/ quantities will be used:
 - Apligraf^{®†}**- up to 5 applications over 5 weeks; **OR**
 - Oasis^{™†} Wound Matrix^{***}- up to 8 applications over 12 weeks.

Based on review of available data, the Company may consider treatment of dystrophic epidermolysis bullosa using the following tissue-engineered skin substitute to be **eligible for coverage**** when **all** of the following criteria are met:

- For mitten-hand deformity associated with dystrophic epidermolysis bullosa; **AND**
- Standard wound therapy has failed; **AND**
- OrCel^{™†} is provided in accordance with the humanitarian device exemption (HDE) specifications of the U.S. Food and Drug Administration [FDA]).****

Based on review of available data, the Company may consider treatment of second- and third-degree burns using the following tissue-engineered skin substitutes to be **eligible for coverage**** when criteria below are met:

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- Epicel^{®†} requested for the treatment of deep dermal or full-thickness burns comprising a total body surface area greater than or equal to 30% when provided in accordance with the HDE specifications of the FDA)****; **OR**
- Integra Dermal Regeneration Template^{™**}.

* Banked human tissue.

** FDA premarket approval.

*** FDA 510(k) cleared.

**** FDA-approved under an HDE.

When Services Are Considered Not Medically Necessary

The use of bioengineered skin and soft tissue substitutes when patient selection criteria are not met is considered to be **not medically necessary**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers all other uses of the bioengineered skin and soft tissue substitutes listed above to be **investigational**.*

Based on review of available data, the Company considers all other skin and soft tissue substitutes not listed above to be **investigational*** including but not limited to:

- ACell^{®†} UBM Hydrated/Lyophilized Wound Dressing
- Ac5 Advanced Wound System (Ac5)
- AlloMend^{™†}
- AlloSkin^{™†}
- AlloSkin^{™†} RT
- Alloskin^{™†} AC
- Apis^{®†}
- Aongen^{™†} Collagen Matrix
- Architect^{®†} ECM, PX, FX
- Artacent^{®†} Wound
- ArthroFlex^{™†} (Flex Graft)
- Atlas Wound Matrix
- Avagen Wound Dressing
- Axoguard^{®†} Nerve Protector (AxoGen)
- BIOBRANE^{™†}
- Biobrane^{®†}/Biobrane-L
- BIOBRANE^{™†} gloves
- Bio-ConneKt^{®†} Wound Matrix
- Cohealyx^{™†} Collagen Dermal Matrix

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- CollaCare^{®†}
- CollaCare^{®†} Dental
- Collagen Wound Dressing (Oasis Research)
- CollaGUARD^{®†}
- CollaMend^{™†}
- CollaWound^{™†}
- Coll-e-derm
- Collexa^{®†}
- Collieva^{®†}
- Conexa^{™†}
- Coreleader Colla-Pad
- CorMatrix^{®†}
- Cymetra[™] (Micronized AlloDerm^{™†})
- Cytal^{™†} (previously MatriStem[®])[†]
- DeNovoSkin^{™†}
- Dermadapt^{™†} Wound Dressing
- Derma-gide
- DermaPure^{™†}
- DermaSpan^{™†}
- DermiSphere^{™†} hDRT
- DressSkin
- Durepair Regeneration Matrix^{®†}
- Endoform Dermal Template^{™†}
- *ENDURAGen*^{™†}
- Excellagen
- ExpressGraft^{™†}
- E-Z Derm^{™†}
- Fibrillar Collagen Wound Dressing
- Flexible Collagen Nerve Cuff (Collagen Matrix, Inc)
- FlowerDerm^{™†}
- Foundation Dermal Regeneration Scaffold (DRS) Solo
- Foundation DRS+ Duo
- Foundation DRS+ Solo
- G4Derm^{™†} Plus
- GammaGraft
- Geistlich Derma-Gide^{™†}
- Gentrix^{™†} Surgical Matrix (previously MatriStem^{®†} Surgical Matrix)
- Graftjacket^{®†} Xpress Flowable Soft Tissue Scaffold
- GraftJacket^{®†} Regenerative Tissue Matrix (also called GraftJacket Skin Substitute)
- Helicoll^{™†}
- Hyalomatrix^{®†}

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- Hyalomatrix^{®†} PA
- hMatrix^{®†}
- InnovaBurn^{®†}
- InnovaMatrix^{®†} FD
- InnovaMatrix fs^{®†}
- InnovaMatrix^{®†} XL
- InnovaMatrix^{®†} PD
- Integra^{TM†} Bilayer Wound Matrix
- Integra^{®†} Matrix Wound Dressing (previously Avagen)
- InteguPly^{®†}
- Keramatrix^{®†}
- Kerecis^{®†} Omega3 MariGen Shield
- Keroxx^{TM†}
- LacertaMatrix
- Marigen^{TM†} Pacto
- MatriDerm^{®†}
- MatriStem^{®†} micormatrix
- Matrix HD^{TM†}
- MicroMatrix^{®†}
- Micromatrix flex
- Miroderm^{®†}
- Miro3D
- Miro3D Fibers Wound Matrix
- Mirotract wound matrix sheet
- Mediskin^{®†}
- MemoDerm^{TM†}
- Microderm^{®†} biologic wound matrix
- Microlyte matrix^{®†}
- Mirragen^{®†}
- Mochida Nerve Cuff (Mochida Pharmaceutical Co.)
- MyOwn skin
- Myriad matrix
- Myriad morcells
- NeoForm^{TM†}
- NeoMatriX^{®†}
- NervAlign Nerve Cuff (Renerve, Ltd)
- Nerve tape (BioCircuit Technologies, Inc)
- Neurawrap (Integra LifeSciences, Corp)
- NeuroMend (Stryker Orthopedics)
- NeuroShield (Monarch bioimplants, GmBH)
- NuCel

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- NovaShield Wound Matrix
- NovosorbTM Biodegradable Temporizing Matrix (BMT)
- Oasis wound Matrix[®]
- Oasis[®] Burn Matrix
- OASIS[®] Ultra
- OlogenTM Collagen Matrix
- Omega3 Wound (originally Merigen wound dressing)
- Omeza[®] Collagen Matrix
- Pelvicol[®]/PelviSoft[®]
- PermacolTM
- PermeaDerm[®] B
- PermeaDerm[®] C
- PermeaDerm[®] Glove
- PhoenixTM Wound Matrix
- PriMatrixTM
- PriMatrixTM Dermal Repair Scaffold
- Progenamatrix
- Puracol[®] and Puracol[®] Plus Collagen Wound Dressings
- PuraPlyTM Wound Matrix (previously FortaDermTM)
- PuraPlyTM AM (Antimicrobial Wound Matrix)
- PuraPly[®] MZ Micronized Wound Matrix (PuraPly[®] MZ)
- Puraply XTTM
- Puros[®] Dermis
- ReCell
- RECELL System
- RegeneProTM
- Reinforce flexible Collagen Nerve Cuff (Collagen Matrix, Inc)
- Repliform[®]
- ReprizaTM
- Restrata[®]
- Restrata MiniMatrix[®]
- Resolve MatrixTM
- SkinTETM
- StrataGraft[®]
- SUPRA SDRM[®]
- Suprathel[®]
- SurgiMend[®]
- SymphonyTM
- Talymed[®]
- TenoGlideTM
- TenSIXTM Acellular Dermal Matrix

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- TissueMend
- TheraForm^{TM†} Standard/Sheet
- TheraGenesis^{®†}
- TransCyte^{TM†}
- TruSkin^{TM†}
- Tutomesh^{TM†} Fenestrated Bovine Pericardium
- Veritas^{®†} Collagen Matrix
- Versawrap nerve protector (Alafair Biosciences, Inc)
- Xcellistem^{®†}
- XCM Biologic^{®†} Tissue Matrix
- XenMatrix^{TM†} AB.

Policy Guidelines

There is no standard definition of “skin substitute”. Products in this review cover products that do not require U.S. Food and Drug Administration (FDA) approval or clearance as well as a number of products cleared through the 510(k) pathway with a variety of FDA product codes. The FDA product codes that include these products are not limited to skin substitute products and may include other indications not related to wounds. The list of products named in this review is not a complete list of all commercially available products.

See the Agency for Healthcare Research and Quality Technology Review by Snyder et al (2020) for detailed description of skin substitute products for treatment of chronic wounds.

Clinical input has indicated that the various acellular dermal matrix products used in breast reconstruction have similar efficacy. The products listed are those that have been identified for use in breast reconstruction. Additional acellular dermal matrix products may become available for this indication.

Non-healing of diabetic wounds is defined as an ulcer that fails to demonstrate greater than 50% wound area reduction after a minimum of 4 weeks of standard wound therapy.

All ulcers subjected to sustained or frequent pressure and stress (ie, pressure-related heel ulcers or medial/lateral foot ulcers) or repetitive moderate pressure (plantar foot ulcers) benefit from pressure reduction, which is accomplished with mechanical offloading. Offloading devices include total contact casts, cast walkers, shoe modifications, and other devices to assist in ambulation.

In published study, AlloPatch was applied weekly for up to 12 weeks. At 6 weeks 65% of the treated diabetic foot ulcers healed (compared with 5% that received standard of care alone). If the patient did not achieve greater than 50% wound closure at 6 weeks, trial participants were withdrawn from the study. At 12 weeks, the proportions of diabetic foot ulcers healed were 80% with AlloPatch and 20% with standard of care. Mean time to heal was 40 days for the AlloPatch group.

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

According to the manufacturer, the safety and the effectiveness of Apligraf have not been established for individuals receiving greater than 5 device applications.

Most studies of Dermagraft reported using up to 8 applications over 12 weeks.

Integra Omnigraft Dermal regeneration Matrix may need second application depending on the progress of wound, however 62% of individuals who received only a single Omnigraft application experienced healing of their wound.

Oasis Wound Matrix per study report had on average 8 applications with number needed to treat for complete wound closure 5 (95% CI ranged from 3-39).

This medical policy addresses bioresorbable nerve wraps (surgical implants) designed to protect and support peripheral nerve healing following end-to-end repair with no gap (e.g., Axoguard^{®†} Nerve Protector by AxoGen indicated for the repair of peripheral nerve injuries where there is no gap). These devices provide a physical barrier that purports to reduce scar formation, reduce mechanical irritation, and promote a favorable environment for nerve regeneration.

Processed nerve allografts and synthetic conduits, e.g., Avance nerve allograft (Axogen), Axoguard nerve connector (Axogen), are addressed in a MP 00926 Peripheral Nerve Injury Repair Using Conduits or Processed Nerve Allografts.

The Women's Health and Cancer Rights Act (WHCRA) helps protect many women with breast cancer who choose to have their breasts rebuilt (reconstructed) after a mastectomy. Mastectomy is surgery to remove all or part of the breast. This federal law requires most group insurance plans that cover mastectomies to also cover breast reconstruction. It was signed into law on October 21, 1998. The United States Departments of Labor and Health and Human Services oversee this law.

Background/Overview

Skin and Soft Tissue Substitutes

Bioengineered skin and soft tissue substitutes may be either acellular or cellular. Acellular products (eg, dermis with cellular material removed) contain a matrix or scaffold composed of materials such as collagen, hyaluronic acid, and fibronectin. Acellular dermal matrix (ADM) products can differ in a number of ways, including as species source (human, bovine, porcine), tissue source (eg dermis, pericardium, intestinal mucosa), additives (eg antibiotics, surfactants), hydration (wet, freeze-dried), and required preparation (multiple rinses, rehydration).

Cellular products contain living cells such as fibroblasts and keratinocytes within a matrix. The cells contained within the matrix may be autologous, allogeneic, or derived from other species (eg, bovine, porcine). Skin substitutes may also be composed of dermal cells, epidermal cells, or a combination of dermal and epidermal cells, and may provide growth factors to stimulate healing. Bioengineered skin substitutes can be used as either temporary or permanent wound coverings.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Applications

There are a large number of potential applications for artificial skin and soft tissue products. One large category is nonhealing wounds, which potentially encompasses diabetic neuropathic ulcers, vascular insufficiency ulcers, and pressure ulcers. A substantial minority of such wounds do not heal adequately with standard wound care, leading to prolonged morbidity and increased risk of mortality. For example, nonhealing lower-extremity wounds represent an ongoing risk for infection, sepsis, limb amputation, and death. Bioengineered skin and soft tissue substitutes have the potential to improve rates of healing and reduce secondary complications.

Other situations in which bioengineered skin products might substitute for living skin grafts include certain postsurgical states (eg, breast reconstruction) in which skin coverage is inadequate for the procedure performed, or for surgical wounds in individuals with compromised ability to heal. Second- and third-degree burns are another indication in which artificial skin products may substitute for auto- or allografts. Certain primary dermatologic conditions that involve large areas of skin breakdown (eg, bullous diseases) may also be conditions in which artificial skin products can be considered as substitutes for skin grafts. ADM products are also being evaluated in the repair of other soft tissues including rotator cuff repair, following oral and facial surgery, hernias, and other conditions.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration (FDA) does not refer to any single product or class of products as “skin substitutes”. Products in this review cover products that do not require FDA approval or clearance as well as a number of products cleared through the 510(k) pathway with a variety of FDA product codes. A large number of artificial skin and soft-tissue products are commercially available or in development. Commercial availability is not a reflection of a product's regulatory status. The following section summarizes a subset of commercially available skin and soft-tissue substitutes. This is not a complete list of all commercially available products. Information on additional products is available in a 2020 Technical Brief on skin substitutes for treating chronic wounds that was commissioned by the Agency for Healthcare Research and Quality.

Acellular Dermal Matrix Products

Allograft ADM products derived from donated cadaveric human skin tissue are supplied by tissue banks compliant with standards of the American Association of Tissue Banks and FDA guidelines. The processing removes the cellular components (ie, epidermis, all viable dermal cells) that can lead to rejection and infection. ADM products from human skin tissue are regarded as minimally processed and not significantly changed in structure from the natural material; FDA classifies ADM products as banked human tissue and, therefore, not requiring FDA approval for homologous use.

In 2017, FDA published clarification of what is considered minimal manipulation and homologous use for human cells, tissues, and cellular and tissue-based products (HCT/Ps)

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

HCT/Ps are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product and applicable regulations and premarket review will be required.

An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

1. "The HCT/P is minimally manipulated;
 2. The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
 3. The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and
 4. Either:
 - i. The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
 - ii. The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and: a) Is for autologous use; b) Is for allogeneic use in a first-degree or second-degree blood relative; or c) Is for reproductive use."
- AlloDerm^{®‡} (LifeCell Corp.) is an ADM (allograft) tissue-replacement product created from native human skin and processed so that the basement membrane and cellular matrix remain intact. Originally, AlloDerm^{®‡} required refrigeration and rehydration before use. It is currently available in a ready-to-use product stored at room temperature. An injectable micronized form of AlloDerm^{®‡} (Cymetra) is available.
 - AlloPatch^{®‡} (Musculoskeletal Transplant Foundation) is an acellular human dermis allograft derived from the reticular layer of the dermis and marketed for wound care. This product is also marketed as FlexHD^{®‡} for postmastectomy breast reconstruction.
 - Cortiva^{®‡} (previously marketed as AlloMax^{™‡} Surgical Graft and before that NeoForm[™])[‡] is an acellular non-cross-linked human dermis allograft.
 - FlexHD^{®‡} and the newer formulation FlexHD^{®‡} Pliable^{™‡} (Musculoskeletal Transplant Foundation) are acellular hydrated reticular dermis allograft derived from donated human skin.
 - DermACELL^{™‡} (LifeNet Health) is an allogeneic ADM processed with proprietary technologies MATRACELL^{®‡} and PRESERVON^{®‡}.
 - DermaMatrix^{™‡} (Synthes) is a freeze-dried ADM derived from donated human skin tissue. DermaMatrix Acellular Dermis is processed by the Musculoskeletal Transplant Foundation.
 - DermaPure^{™‡} (Tissue Regenix Wound Care) is a single-layer decellularized human dermal allograft for the treatment of acute and chronic wounds.
 - GraftJacket^{®‡} Regenerative Tissue Matrix (also called GraftJacket Skin Substitute; KCI) is an acellular regenerative tissue matrix that has been processed from human skin supplied

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

from U.S. tissue banks. The allograft is minimally processed to remove the epidermal and dermal cells while preserving dermal structure. GraftJacket Xpress^{®‡} is an injectable product

- mVASC^{®‡} (MicroVascular Tissues, Inc.) is a microvascular tissue structural allograft made of small blood vessels and extracellular matrix, inherent non-viable cells, and associated biological signaling factors harvested from subcutaneous tissue of cadaveric human donors.
- TheraSkin^{®‡} (LifeNet Health) is a cryopreserved split-thickness human skin allograft composed of living fibroblasts and keratinocytes and an extracellular matrix in epidermal and dermal layers. TheraSkin^{®‡} is derived from human skin allograft supplied by tissue banks compliant with the American Association of Tissue Banks and FDA guidelines. It is considered a minimally processed human cell, tissue, and cellular- and tissue-based product by the FDA.

Although frequently used by surgeons for breast reconstruction, FDA does not consider this homologous use and has not cleared or approved any surgical mesh device (synthetic, animal collagen-derived, or human collagen-derived) for use in breast surgery. The indication of surgical mesh for general use in “Plastic and reconstructive surgery” was cleared by the FDA before surgical mesh was described for breast reconstruction in 2005. FDA states that the specific use of surgical mesh in breast procedures represents a new intended use and that a substantial equivalence evaluation via 510(k) review is not appropriate and a pre-market approval evaluation is required.

In March 2019, the FDA held an Advisory Committee meeting on breast implants, at which time the panel noted that while there is data about ADM for breast reconstruction, the FDA has not yet determined the safety and effectiveness of ADM use for breast reconstruction. The panel recommended that patients are informed and also recommended studies to assess the benefit and risk of ADM use in breast reconstruction.

In March 2021, FDA issued a Safety Communication to inform patients, caregivers, and health care providers that certain ADM products used in implant-based breast reconstruction may have a higher chance for complications or problems. An FDA analysis of patient-level data from real-world use of ADMs for implant-based breast reconstruction suggested that 2 ADMs—FlexHD and Allomax—may have a higher risk profile than others.

In October 2021, an FDA advisory panel on general and plastic surgery voted against recommending FDA approval of the SurgiMend mesh for the specific indication of breast reconstruction. The advisory panel concluded that the benefits of using the device did not outweigh the risks

FDA product codes: FTM, OXF.

Xenogeneic Products

Cytal^{™‡} (previously called MatriStem^{®‡}) Wound Matrix, Multilayer Wound Matrix, Pelvic Floor Matrix, MicroMatrix, and Burn Matrix (all manufactured by ACell) are composed of porcine-derived urinary bladder matrix.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Helicoll (Encol) is an acellular collagen matrix derived from bovine dermis. In 2004, it was cleared for marketing by the FDA through the 510(k) process for topical wound management that includes partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears), and surgical wounds including donor sites/grafts.

Keramatrix^{®†} (Keraplast Research) is an open-cell foam comprised of freeze-dried keratin that is derived from acellular animal protein. In 2009, it was cleared for marketing by the FDA through the 510(k) process under the name of Keratec. The wound dressings are indicated in the management of the following types of dry, light, and moderately exudating partial and full-thickness wounds: pressure (stage I to IV) and venous stasis ulcers, ulcers caused by mixed vascular etiologies, diabetic ulcers, donor sites, and grafts.

Kerecis^{™†} Omega3 Wound (Kerecis) is an ADM derived from fish skin. It has a high content of omega 3 fatty acids and is intended for use in burn wounds, chronic wounds, and other applications.

Oasis^{™†} Wound Matrix (Cook Biotech) is a collagen scaffold (extracellular matrix) derived from porcine small intestinal submucosa. In 2000, it was cleared for marketing by the FDA through the 510(k) process for the management of partial- and full-thickness wounds, including pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled undermined wounds, surgical wounds, trauma wounds, and draining wounds.

Permacol^{™†} (Covidien) is xenogeneic and composed of cross-linked porcine dermal collagen. Cross-linking improves tensile strength and long-term durability but decreases pliability.

PriMatrix^{™†} (TEI Biosciences; a subsidiary of Integra Life Sciences) is a xenogeneic ADM processed from fetal bovine dermis. It was cleared for marketing by the FDA through the 510(k) process for partial- and full-thickness wounds; diabetic, pressure, and venous stasis ulcers; surgical wounds; and tunneling, draining, and traumatic wounds.

SurgiMend^{®†} PRS (TEI Biosciences, a subsidiary of Integra Life Sciences) is a xenogeneic ADM processed from fetal and neonatal bovine dermis.

Strattice^{™†} Reconstructive Tissue Matrix (LifeCell Corp.) is a xenogeneic non-cross-linked porcine-derived ADM. There are pliable and firm versions, which are stored at room temperature and come fully hydrated.

FDA Product codes: KGN, FTL, FTM.

Living Cell Therapy

Apligraf^{®†} (Organogenesis) is a bilayered living cell therapy composed of an epidermal layer of living human keratinocytes and a dermal layer of living human fibroblasts. Apligraf^{®†} is supplied as needed, in 1 size, with a shelf-life of 10 days. In 1998, it was approved by the FDA for use in conjunction with compression therapy for the treatment of noninfected, partial- and full-thickness

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

skin ulcers due to venous insufficiency and in 2001 for full-thickness neuropathic diabetic lower-extremity ulcers nonresponsive to standard wound therapy.

DermaGraft[®]† (Organogenesis) is composed of cryopreserved human-derived fibroblasts and collagen derived from newborn human foreskin and cultured on a bioabsorbable polyglactin mesh scaffold. DermaGraft has been approved by the FDA for repair of diabetic foot ulcers.

Epicel[®]† (Genzyme Biosurgery) is an epithelial autograft composed of a patient's own keratinocytes cultured ex vivo and is FDA-approved under a humanitarian device exemption for the treatment of deep dermal or full-thickness burns comprising a total body surface area of 30% or more. It may be used in conjunction with split-thickness autografts or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns.

OrCel[™]† (Forticell Bioscience; formerly Composite Cultured Skin) is an absorbable allogeneic bilayered cellular matrix, made of bovine collagen, in which human dermal cells have been cultured. It was approved by FDA premarket approval for healing donor site wounds in burn victims and under a humanitarian device exemption for use in patients with recessive dystrophic epidermolysis bullosa undergoing hand reconstruction surgery to close and heal wounds created by the surgery, including those at donor sites.

FDA product codes: FTM, PFC, OCE, ODS.

Autologous Cell Harvesting Device

Recell[®]† (Avita Medical) was initially approved by the FDA in September 2018 under the premarket approval (PMA) process (PMA BP170122). It is an autologous cell harvesting device indicated for the treatment of acute partial-thickness thermal burn wound when used by an appropriately-licensed healthcare professional at the patient's point of care to prepare autologous RES Regenerative Epidermal Suspension. The initial indication was for use in patients 18 years of age and older in combination with meshed autografting. Subsequently, indications were expanded to include direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric as well as adult patients and for full-thickness skin defects after traumatic avulsion (e.g., degloving) or surgical excision (e.g., necrotizing tissue infection) or resection (e.g., skin cancer) in patients 15 years of age and older.

FDA product code: QCZ.

Biosynthetic Products

Biobrane[®]†/Biobrane-L (Smith & Nephew) is a biosynthetic wound dressing constructed of a silicon film with a nylon fabric partially embedded into the film. The fabric creates a complex 3-dimensional structure of trifilament thread, which chemically binds collagen. Blood/sera clot in the nylon matrix, adhering the dressing to the wound until epithelialization occurs.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Integra^{®‡} Dermal Regeneration Template (also marketed as Omnigraft Dermal Regeneration Matrix; Integra LifeSciences) is a bovine, collagen/glycosaminoglycan dermal replacement covered by a silicone temporary epidermal substitute. It was approved by the FDA for use in the post excisional treatment of life-threatening full-thickness or deep partial-thickness thermal injury where sufficient autograft is not available at the time of excision or not desirable because of the physiologic condition of the patient, and for certain diabetic foot ulcers. Integra^{®‡} Matrix Wound Dressing and Integra^{®‡} Meshed Bilayer Wound Matrix are substantially equivalent skin substitutes and were cleared for marketing by the FDA through the 510(k) process for other indications. Integra^{®‡} Bilayer Matrix Wound Dressing (Integra LifeSciences) is designed to be used in conjunction with negative pressure wound therapy. The meshed bilayer provides a flexible wound covering and allows drainage of wound exudate.

TransCyte^{™‡} (Advanced Tissue Sciences) consists of human dermal fibroblasts grown on nylon mesh, combined with a synthetic epidermal layer, and was approved by the FDA in 1997. TransCyte is intended as a temporary covering over burns until autografting is possible. It can also be used as a temporary covering for some burn wounds that heal without autografting.

FDA product codes: FRO, MDD, MGR.

Synthetic Products

Suprathel^{®‡} (PolyMedics Innovations) is a synthetic copolymer membrane fabricated from a tripolymer of polylactide, trimethylene carbonate, and s-caprolactone. It is used to provide temporary coverage of superficial dermal burns and wounds. Suprathel^{®‡} is covered with gauze and a dressing that is left in place until the wound has healed.

Nerve Wraps

Nerve wraps can be used for peripheral nerve repair. They are often made from biocompatible materials like collagen, designed to encase injured peripheral nerves. It provides a barrier between the nerve and surrounding tissue, minimizing scarring and promoting a conducive environment for nerve healing. Their application is ideal for cases where the nerve is intact, but needs protection from scarring or compression.

AxoGuard^{®‡} nerve connector (Axogen, Inc) is an implant derived from small intestine submucosa designed to protect injured and compressed nerves. Other FDA 510K approved nerve wraps include: Flexibile Collagen Nerve Cuff (Collagen Matrix, Inc), Mochida Nerve Cuff (Mochida Pharmaceutical Co.), NervAlign Nerve Cuff (Renerve, Ltd), Nerve tape (BioCircuit Technologies, Inc), Neurawrap (Integra LifeSciences, Corp), NeuroMend (Stryker Orthopedics), NeuroShield (Monarch bioimplants, GmbH), Reinforce flexible Collagen Nerve Cuff (Collagen Matrix, Inc), and Versawrap nerve protector (Alafair Biosciences, Inc).

FDA product code: JXI.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Bioengineered skin and soft tissue substitutes may be derived from human tissue (autologous or allogeneic), nonhuman tissue (xenographic), synthetic materials, or a composite of these materials. Bioengineered skin and soft tissue substitutes are being evaluated for a variety of conditions, including breast reconstruction and healing lower-extremity ulcers and severe burns. Acellular dermal matrix (ADM) products are also being evaluated for soft tissue repair.

Summary of Evidence

Breast Reconstruction

For individuals who are undergoing breast reconstruction who receive allogeneic acellular dermal matrix (ADM) products, the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life (QOL), and treatment-related morbidity. A systematic review found no difference in overall complication rates with ADM allograft compared with standard procedures for breast reconstruction. Reconstructions with ADM have been reported to have higher seroma, infection, and necrosis rates than reconstructions without ADM. However, capsular contracture and malposition of implants may be reduced. Thus, in cases where there is limited tissue coverage, the available evidence may inform patient decision making about reconstruction options. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Tendon Repair

For individuals who are undergoing tendon repair who receive GraftJacket, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity. The RCT identified found improved outcomes with the GraftJacket ADM allograft for rotator cuff repair. Although these results were positive, additional studies with a larger number of patients is needed to evaluate the consistency of the effect. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Surgical Repair of Hernias or Parastomal Reinforcement

For individuals who are undergoing surgical repair of hernias or parastomal reinforcement who receive acellular collagen-based scaffolds, the evidence includes RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity. Several comparative studies including RCTs have shown no difference in outcomes between tissue-engineered skin substitutes and either standard synthetic mesh or no reinforcement. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Diabetic Lower-Extremity Ulcers

For individuals who have diabetic lower-extremity ulcers who receive AlloPatch, Apligraf, Dermagraft, Integra, mVASC, TheraSkin, or Kerecis Omega3, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. Randomized controlled trials reporting complete wound healing outcomes with at least 12 weeks of follow-up have demonstrated the efficacy of AlloPatch (reticular ADM), Apligraf and Dermagraft (living cell therapy), Integra (biosynthetic), mVASC, TheraSkin, and Omega3 Wound (Kerecis) over the standard of care (SOC). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have diabetic lower-extremity ulcers who receive skin substitutes other than AlloPatch, Apligraf, Dermagraft, Integra, mVASC, TheraSkin, or Kerecis Omega3, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. Results from a multicenter RCT showed some benefit of DermACELL that was primarily for the subgroup of patients who only required a single application of the ADM. Studies are needed to further define the population who might benefit from this treatment. Additional study with a larger number of subjects is needed to evaluate the effect of GraftJacket, DermACELL, Cytal, PriMatrix, and Oasis Wound Matrix, compared with current SOC or other advanced wound therapies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Lower-Extremity Ulcers due to Venous Insufficiency

For individuals who have lower-extremity ulcers due to venous insufficiency who receive Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. Randomized controlled trials have demonstrated the efficacy of Apligraf living cell therapy and xenogeneic Oasis Wound Matrix over the SOC. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive bioengineered skin substitutes other than Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and QOL. In a moderately large RCT, Dermagraft was not shown to be more effective than controls for the primary or secondary endpoints in the entire population and was only slightly more effective than controls (an 8% to 15% increase in healing) in subgroups of patients with ulcer durations of 12 months or less or size of 10 cm or less. Additional studies with a larger number of subjects is needed to evaluate the effect of the xenogeneic PriMatrix skin substitute versus the current SOC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Deep Dermal Burns

For individuals who have deep dermal burns who receive bioengineered skin substitutes (ie, Epicel, Integra Dermal Regeneration Template), the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, QOL, and treatment-

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

related morbidity. Overall, few skin substitutes have been approved, and the evidence is limited for each product. Epicel (living cell therapy) has received U.S. Food and Drug Administration approval under a humanitarian device exemption for the treatment of deep dermal or full-thickness burns comprising a total body surface area of 30% or more. Comparative studies have demonstrated improved outcomes for biosynthetic skin substitute Integra Dermal Regeneration Template for the treatment of burns. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have deep dermal burns who are treated with the ReCell autologous cell harvesting device, the evidence includes RCTs. One RCT evaluated ReCell as an adjunct to meshed autologous skin grafting and the other compared ReCell head-to-head with skin grafting. Although the ReCell device was comparable to standard care on outcomes such as complete wound closure, confidence in the strength of the overall body of evidence is limited by individual study limitations and heterogeneity of populations, interventions, and outcome measures across studies. Additional RCT evidence in the intended use population is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Dystrophic Epidermolysis Bullosa

For individuals who have dystrophic epidermolysis bullosa who receive OrCel, the evidence includes a case series. Relevant outcomes are symptoms, change in disease status, morbid events, and QOL. OrCel was approved under a humanitarian drug exemption for use in patients with dystrophic epidermolysis bullosa undergoing hand reconstruction surgery, to close and heal wounds created by the surgery, including those at donor sites. Outcomes have been reported in a small series (eg, 5 patients). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Institute for Health and Care Excellence

In 2023, NICE updated its guidance on the prevention and management of diabetic foot problems. The Institute recommended that clinicians “consider dermal or skin substitutes as an adjunct to standard care when treating diabetic foot ulcers, only when healing has not progressed and on the advice of the multidisciplinary foot care service.”

In 2019, NICE published guidance on the ReCell system for treating skin loss, scarring, and depigmentation after burn injury. The guidance recommended that additional research was needed to address the uncertainties regarding the potential benefits of ReCell.

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services (CMS) issued the following national coverage determination: porcine (pig) skin dressings are covered, if reasonable and necessary for the individual patient as an occlusive dressing for burns, donor sites of a homograft, and decubiti and other ulcers.

In 2019, CMS reported that it is finalizing the proposal to continue the policy established in calendar year (CY) 2018 to assign skin substitutes to the low cost or high-cost group. In addition, CMS presented several payment ideas to change how skin substitute products are paid and solicited comments on these ideas to be used for future rulemaking. In 2022, CMS proposed changing the terminology of skin substitutes to "wound care management products", and to treat and pay for these products as incident to supplies under the Physician Fee Schedule (PFS) beginning on January 1, 2024. However, in November 2022, CMS posted this update on the process: "After reviewing comments on the proposals, we understand that it would be beneficial to provide interested parties more opportunity to comment on the specific details of changes in coding and payment mechanisms prior to finalizing a specific date when the transition to more appropriate and consistent payment and coding for these products will be completed. We plan to conduct a Town Hall in early CY 2023 with interested parties to address commenters' concerns as well as discuss potential approaches to the methodology for payment of skin substitute products under the PFS. We will take into account the comments we received in response to CY 2023 rulemaking and feedback received in association with the Town Hall in order to strengthen proposed policies for skin substitutes in future rulemaking."

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT04322370	Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries	42	May 2027
NCT06616844 ^a	Evaluating the Efficacy of Porcine Placental Extracellular Matrix Augmented Wound Care Against Standard Wound Care for the Management of Diabetic Foot Ulcers: a Multi-center, Prospective, Observer-blinded, Randomized Controlled Clinical Trial.	194	Jul 2026

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT06449638 ^a	A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Multiple Human Placental-Based Skin Substitutes and Standard of Care Versus SOC Alone in the Treatment of Hard-to-Heal Diabetic Foot Ulcers	272	AugDec 2026
NCT06831760	A Randomized, Controlled Clinical Trial Evaluating the Efficacy of Type-I Collagen-based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Venous Leg Ulcers	5060	Jun 2026Jul 2025
NCT06745557 ^a	A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of DenovoSkin ^{TM†} , a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients with Deep Partial and Full-thickness Burns	70	Jun 2028
NCT06557122 ^a	A Randomized Controlled Clinical Trial Evaluating the Efficacy of a Unique Advanced Bioengineered Skin Substitute With Standard of Care Versus an Active Comparator With Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers	24	Oct 2024
NCT05291169	A Randomized, Multicenter, Open Label Study Comparing Omeza Combination Therapy with Standard of Care to Standard of Care alone for Chronic Venous Leg Ulcers over the course of 4 weeks	54 (actual)	Mar 2024
NCT05084183	An Adaptive, Randomized, Controlled Trial Evaluating the Effectiveness of PermeaDerm ^{®†} (PD) as Compared to Mepilex Ag ^{®†} Used as Standard of Care in the Treatment of Adult and Pediatric Partial Thickness Burns	68	Nov 2023
NCT05439746	Clinical Trial to Assess the Efficacy of Microlyte Matrix on the Healing of Surgically Created Partial Thickness Donor Site Wounds on Patients Requiring Split-thickness Skin Grafting	53	Jan 2024

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05506215	A Prospective, Multicenter, Open Label, Randomized, Controlled Clinical Study Evaluating the Effect of NovoSorb [®] SynPath [™] Dermal Matrix Compared to Standard of Care (SOC) In the Treatment of Nonresponsive, Chronic Diabetic Foot Ulcers.	25 (terminated)	Feb 2024
NCT05372809	Closure Obtained With Vascularized Epithelial Regeneration for DFUs With SkinTE [®]	42 (terminated)	Feb 2024
NCT02587403 ^a	A Randomized, Prospective Study Comparing Fortiva [™] Porcine Dermis vs. Strattice [™] Reconstructive Tissue Matrix in Patients Undergoing Complex Open Primary Ventral Hernia Repair	120	Sept 2023
NCT04927702	Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix (Restrata [®]) [‡] With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute (Apligraf [®]) [‡] in Treating Venous Leg Ulcers (VLU)	47 (terminated)	Aug 2024
NCT06035536	A Multi-Center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With Symphony [™] Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers	120143	Dec 2024Nov 2025
NCT05517902	A Phase 3 Multicenter, Single-Arm, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of StrataGraft [®] Construct in Pediatric Subjects With Deep Partial Thickness (DPT) Thermal Burns	1 (actual)	May 2024
NCT04090424	A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb [®] Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries	150	Dec 20252026
NCT03394612	A Phase II, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF; denovoSkin) for the Treatment of Full-Thickness Defects in Adults and Children in	20	Dec 2026

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
	Comparison to Autologous Split-thickness Skin Grafts (STSG)		
<i>Unpublished</i>			
NCT06470087	A Randomized Controlled Clinical Trial Comparing High Purity Type-I Collagen-based Skin Substitute to Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers	28	Sept 2024
NCT02322554	The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers	50,000	Jan 2020
NCT03935386 ^a	A Prospective Randomized Clinical Trial Comparing Multi-layer Bandage Compression Therapy With and Without a Biologically Active Human Skin Allograft (Theraskin) for the Treatment of Chronic Venous Leg Ulcers	100	Dec 2020
NCT03589586 ^a	An Open-Label Trial to Assess the Clinical Effectiveness of DermACELL AWM in Subjects With Chronic Venous Leg Ulcers	100	Mar 2021
NCT03881254	A Multi-center, Randomized Controlled Clinical Trial Evaluating the Effects of SkinTE ^{TM†} in the Treatment of Wagner One Diabetic Foot Ulcers	100	Jul 2021
NCT04198441	A Randomized, Multicenter, Open Label Study Comparing the Omeza ^{®‡} Products Bundle to Standard of Care for Chronic Venous Leg Ulcers and Chronic Diabetic Foot Ulcers	78	Dec 2021
NCT04537520 ^a	Interventional Multi-Center Post Market Randomized Controlled Open-Label Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Hard to Heal Diabetic Foot Wounds	180	Dec 2022
NCT04918784	Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix (Restrata ^{®‡} , Acera Surgical, Inc.) With Standard of Care in Treating Diabetic Foot Ulcer	46	Dec 2022
NCT05883098	Effectiveness of Supra SDRM ^{®‡} vs. Fibracol Plus Collagen in the Treatment of Diabetic Foot Ulcers: a Pilot Randomized Controlled Trial	30	Jun 2023

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

References

1. Snyder DL, Sullivan N, Margolis DJ, Schoelles K. Skin substitutes for treating chronic wounds. Technology Assessment Program Project ID No. WNDT0818. (Prepared by the ECRI Institute-Penn Medicine Evidence-based Practice Center under Contract No. HHSA 290-2015-00005-I) Rockville, MD: Agency for Healthcare Research and Quality. February 2020. Available at: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/skin-substitute_0.pdf.
2. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. December 2017. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal>.
3. U.S. Food and Drug Administration. Executive Summary Breast Implant Special Topics. March 2019. <https://wayback.archive-it.org/7993/20201226003814/https://www.fda.gov/media/122956/download>.
4. U.S. Food & Drug Administration. Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates: FDA Safety Communication. March 2021. <https://web.archive.org/web/20210331181103/http://www.fda.gov/medical-devices/safety-communications/acellular-dermal-matrix-adm-products-used-implant-based-breast-reconstruction-differ-complication>.
5. U.S. Food and Drug Administration. General and Plastic Surgery Devices Advisory Committee Meeting. October 20, 2021. <https://www.fda.gov/media/153413/download>.
6. Davila AA, Seth AK, Wang E, et al. Human Acellular Dermis versus Submuscular Tissue Expander Breast Reconstruction: A Multivariate Analysis of Short-Term Complications. Arch Plast Surg. Jan 2013; 40(1): 19-27. PMID 23362476
7. Ng TP, Loo BYK, Yong N, et al. Review: Implant-Based Breast Reconstruction After Mastectomy for Breast Cancer: A Meta-analysis of Randomized Controlled Trials and Prospective Studies Comparing Use of Acellular Dermal Matrix (ADM) Versus Without ADM. Ann Surg Oncol. May 2024; 31(5): 3366-3376. PMID 38285304
8. Lee KT, Mun GH. Updated Evidence of Acellular Dermal Matrix Use for Implant-Based Breast Reconstruction: A Meta-analysis. Ann Surg Oncol. Feb 2016; 23(2): 600-10. PMID 26438439
9. McCarthy CM, Lee CN, Halvorson EG, et al. The use of acellular dermal matrices in two-stage expander/implant reconstruction: a multicenter, blinded, randomized controlled trial. Plast Reconstr Surg. Nov 2012; 130(5 Suppl 2): 57S-66S. PMID 23096987
10. Hinchcliff KM, Orbay H, Busse BK, et al. Comparison of two cadaveric acellular dermal matrices for immediate breast reconstruction: A prospective randomized trial. J Plast Reconstr Aesthet Surg. May 2017; 70(5): 568-576. PMID 28341592
11. Mendenhall SD, Anderson LA, Ying J, et al. The BREASTrial Stage II: ADM Breast Reconstruction Outcomes from Definitive Reconstruction to 3 Months Postoperative. Plast Reconstr Surg Glob Open. Jan 2017; 5(1): e1209. PMID 28203509

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

12. Mendenhall SD, Moss WD, Graham EM, et al. The BREASTrial Stage III: Acellular Dermal Matrix Breast Reconstruction Outcomes from 3 Months to 2 Years Postoperatively. *Plast Reconstr Surg.* Jan 01 2023; 151(1): 17-24. PMID 36194057
13. Davison SP, Harbour S, Fasshi E. Comparison of Different Acellular Dermal Matrix in Breast Reconstruction: A Skin-to-Skin Study. *Aesthet Surg J.* Jul 15 2024; 44(8): 829-837. PMID 38377366
14. Keane AM, Chiang SN, Tao Y, et al. Cortiva versus AlloDerm in Prepectoral and Partial Submuscular Implant-Based Breast Reconstruction: A Randomized Clinical Trial. *Plast Reconstr Surg.* Oct 01 2024; 154(4S): 13S-26S. PMID 38085977
15. Dikmans RE, Negenborn VL, Bouman MB, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. *Lancet Oncol.* Feb 2017; 18(2): 251-258. PMID 28012977
16. Barber FA, Burns JP, Deutsch A, et al. A prospective, randomized evaluation of acellular human dermal matrix augmentation for arthroscopic rotator cuff repair. *Arthroscopy.* Jan 2012; 28(1): 8-15. PMID 21978432
17. Rashid MS, Smith RDJ, Nagra N, et al. Rotator cuff repair with biological graft augmentation causes adverse tissue outcomes. *Acta Orthop.* Dec 2020; 91(6): 782-788. PMID 32691656
18. Bellows CF, Smith A, Malsbury J, et al. Repair of incisional hernias with biological prosthesis: a systematic review of current evidence. *Am J Surg.* Jan 2013; 205(1): 85-101. PMID 22867726
19. Espinosa-de-los-Monteros A, de la Torre JI, Marrero I, et al. Utilization of human cadaveric acellular dermis for abdominal hernia reconstruction. *Ann Plast Surg.* Mar 2007; 58(3): 264-7. PMID 17471129
20. Gupta A, Zahriya K, Mullens PL, et al. Ventral herniorrhaphy: experience with two different biosynthetic mesh materials, Surgisis and Alloderm. *Hernia.* Oct 2006; 10(5): 419-25. PMID 16924395
21. Bochicchio GV, De Castro GP, Bochicchio KM, et al. Comparison study of acellular dermal matrices in complicated hernia surgery. *J Am Coll Surg.* Oct 2013; 217(4): 606-13. PMID 23973102
22. Roth JS, Zachem A, Plymale MA, et al. Complex Ventral Hernia Repair with Acellular Dermal Matrices: Clinical and Quality of Life Outcomes. *Am Surg.* Feb 01 2017; 83(2): 141-147. PMID 28228200
23. Bellows CF, Shadduck P, Helton WS, et al. Early report of a randomized comparative clinical trial of StratticeTM reconstructive tissue matrix to lightweight synthetic mesh in the repair of inguinal hernias. *Hernia.* Apr 2014; 18(2): 221-30. PMID 23543334
24. Dhanani NH, Lyons NB, Lee KH, et al. Synthetic Versus Biologic Mesh for Complex Open Ventral Hernia Repair: 3-Year Follow-Up of a Pilot Randomized Controlled Trial. *HCA Healthc J Med.* 2025; 6(1): 43-50. PMID 40071184
25. Seefeldt CS, Knievel J, Deeb M, et al. Biological vs Synthetic Mesh in Laparoendoscopic Inguinal Hernia Repair: The BIOLAP Randomized Clinical Trial. *JAMA Surg.* Dec 01 2025; 160(12): 1309-1316. PMID 41060645
26. Remulla D, Carvalho A, Birrell AM, et al. Mesh-related Outcomes of Biologic Versus Synthetic Mesh for Single-stage Repair of Contaminated Ventral Hernias: A 5 to 10-year Analysis of a Randomized Controlled Trial. *Ann Surg.* Mar 01 2026; 283(3): 390-397. PMID 40792628

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

27. Fleshman JW, Beck DE, Hyman N, et al. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. *Dis Colon Rectum*. May 2014; 57(5): 623-31. PMID 24819103
28. Kalaiselvan R, Carlson GL, Hayes S, et al. Recurrent intestinal fistulation after porcine acellular dermal matrix reinforcement in enteric fistula takedown and simultaneous abdominal wall reconstruction. *Hernia*. Jun 2020; 24(3): 537-543. PMID 31811593
29. Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. *Cochrane Database Syst Rev*. Feb 11 2016; 2(2): CD011255. PMID 26866804
30. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. *Diabetes Care*. Feb 2001; 24(2): 290-5. PMID 11213881
31. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. *Diabetes Care*. Jun 2003; 26(6): 1701-5. PMID 12766097
32. Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. *Adv Skin Wound Care*. Jan 2015; 28(1): 17-20. PMID 25407083
33. Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. *Int Wound J*. Apr 2017; 14(2): 307-315. PMID 27073000
34. Zelen CM, Orgill DP, Serena TE, et al. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. *Int Wound J*. Oct 2018; 15(5): 731-739. PMID 29682897
35. Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. *Wound Repair Regen*. 2015; 23(6): 891-900. PMID 26297933
36. Campitiello F, Mancone M, Della Corte A, et al. To evaluate the efficacy of an acellular Flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. *Updates Surg*. Dec 2017; 69(4): 523-529. PMID 28497218
37. Gould LJ, Orgill DP, Armstrong DG, et al. Improved healing of chronic diabetic foot wounds in a prospective randomised controlled multi-centre clinical trial with a microvascular tissue allograft. *Int Wound J*. May 2022; 19(4): 811-825. PMID 34469077
38. Armstrong DG, Galiano RD, Orgill DP, et al. Multi-centre prospective randomised controlled clinical trial to evaluate a bioactive split thickness skin allograft vs standard of care in the treatment of diabetic foot ulcers. *Int Wound J*. May 2022; 19(4): 932-944. PMID 35080127
39. Sanders L, Landsman AS, Landsman A, et al. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. *Ostomy Wound Manage*. Sep 2014; 60(9): 26-38. PMID 25211605
40. DiDomenico L, Landsman AR, Emch KJ, et al. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. *Wounds*. Jul 2011; 23(7): 184-9. PMID 25879172

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

41. Brigido SA, Boc SF, Lopez RC. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. *Orthopedics*. Jan 2004; 27(1 Suppl): s145-9. PMID 14763548
42. Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. *Int Wound J*. Jun 2009; 6(3): 196-208. PMID 19368581
43. Reyzelman AM, Bazarov I. Human acellular dermal wound matrix for treatment of DFU: literature review and analysis. *J Wound Care*. Mar 2015; 24(3): 128; 129-34. PMID 25764957
44. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. *Int Wound J*. Sep 2006; 3(3): 181-7. PMID 16984575
45. Walters J, Cazzell S, Pham H, et al. Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers. *Eplasty*. 2016; 16: e10. PMID 26933467
46. Cazzell S, Vayser D, Pham H, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. *Wound Repair Regen*. May 2017; 25(3): 483-497. PMID 28544150
47. Frykberg RG, Cazzell SM, Arroyo-Rivera J, et al. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis. *J Wound Care*. Jul 2016; 25 Suppl 7: S18-25. PMID 27410467
48. Lantis JC, Snyder R, Reyzelman AM, et al. Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: a prospective randomised controlled trial. *J Wound Care*. Jul 01 2021; 30(Sup7): S18-S27. PMID 34256588
49. Niezgoda JA, Van Gils CC, Frykberg RG, et al. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. *Adv Skin Wound Care*. Jun 2005; 18(5 Pt 1): 258-66. PMID 15942317
50. Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. *Int J Low Extrem Wounds*. Jun 2011; 10(2): 80-5. PMID 21693443
51. Armstrong DG, Orgill DP, Galiano RD, et al. A multi-centre, single-blinded randomised controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of diabetic foot ulcers. *Int Wound J*. May 2022; 19(4): 791-801. PMID 34418302
52. Armstrong DG, Orgill DP, Galiano RD, et al. A Borate-Based Bioactive Glass Advances Wound Healing in Non-Healing Wagner Grade 1 Diabetic Foot Ulcers: A Randomised Controlled Clinical Trial. *Int Wound J*. Oct 2025; 22(10): e70763. PMID 41014175
53. Ruiz-Muñoz M, Martinez-Barrios FJ, Cervera-Garvi P, et al. Fish skin grafts versus standard of care on wound healing of chronic diabetic foot ulcers: A systematic review and meta-analysis. *Prim Care Diabetes*. Jun 2024; 18(3): 291-298. PMID 38644082
54. Lullove EJ, Liden B, Winters C, et al. A Multicenter, Blinded, Randomized Controlled Clinical Trial Evaluating the Effect of Omega-3-Rich Fish Skin in the Treatment of Chronic, Nonresponsive Diabetic Foot Ulcers. *Wounds*. Jul 2021; 33(7): 169-177. PMID 33872197

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

55. Lullove EJ, Liden B, McEneaney P, et al. Evaluating the effect of omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers: penultimate analysis of a multicenter, prospective, randomized controlled trial. *Wounds*. Apr 2022; 34(4): E34-E36. PMID 35797557
56. Lantis Ii JC, Lullove EJ, Liden B, et al. Final efficacy and cost analysis of a fish skin graft vs standard of care in the management of chronic diabetic foot ulcers: a prospective, multicenter, randomized controlled clinical trial. *Wounds*. Apr 2023; 35(4): 71-79. PMID 37023475
57. Dardari D, Piaggese A, Potier L, et al. Intact Fish Skin Graft to Treat Deep Diabetic Foot Ulcers. *NEJM Evid*. Dec 2024; 3(12): EVIDoa2400171. PMID 39365895
58. O'Meara S, Cullum N, Nelson EA, et al. Compression for venous leg ulcers. *Cochrane Database Syst Rev*. Nov 14 2012; 11(11): CD000265. PMID 23152202
59. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. *Arch Dermatol*. Mar 1998; 134(3): 293-300. PMID 9521027
60. Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. *J Vasc Surg*. May 2005; 41(5): 837-43. PMID 15886669
61. Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. *Int Wound J*. Mar 2007; 4(1): 3-7. PMID 17425543
62. Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. *Adv Skin Wound Care*. Jan 2010; 23(1): 34-8. PMID 20101114
63. Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. *Int Wound J*. Apr 2013; 10(2): 132-7. PMID 23506344
64. Cazzell S. A Randomized Controlled Trial Comparing a Human Acellular Dermal Matrix Versus Conventional Care for the Treatment of Venous Leg Ulcers. *Wounds*. Mar 2019; 31(3): 68-74. PMID 30720443
65. Carsin H, Ainaud P, Le Bever H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. *Burns*. Jun 2000; 26(4): 379-87. PMID 10751706
66. Lagus H, Sarlomo-Rikala M, Böhling T, et al. Prospective study on burns treated with Integra®, a cellulose sponge and split thickness skin graft: comparative clinical and histological study--randomized controlled trial. *Burns*. Dec 2013; 39(8): 1577-87. PMID 23880091
67. Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. *Crit Care Med*. Nov 2007; 35(11): 2615-23. PMID 17828040
68. Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. *J Burn Care Rehabil*. 2003; 24(1): 42-8. PMID 12543990
69. Hicks KE, Huynh MN, Jeschke M, et al. Dermal regenerative matrix use in burn patients: A systematic review. *J Plast Reconstr Aesthet Surg*. Nov 2019; 72(11): 1741-1751. PMID 31492583

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

70. Gonzalez SR, Wolter KG, Yuen JC. Infectious Complications Associated with the Use of Integra: A Systematic Review of the Literature. *Plast Reconstr Surg Glob Open*. Jul 2020; 8(7): e2869. PMID 32802634
71. Luze H, Nischwitz SP, Smolle C, et al. The Use of Acellular Fish Skin Grafts in Burn Wound Management-A Systematic Review. *Medicina (Kaunas)*. Jul 09 2022; 58(7). PMID 35888631
72. Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL[®] System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. *Burns*. Jun 2019; 45(4): 772-782. PMID 30578048
73. Holmes Iv JH, Molnar JA, Carter JE, et al. A Comparative Study of the ReCell[®] Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. *J Burn Care Res*. Aug 17 2018; 39(5): 694-702. PMID 29800234
74. Fivenson DP, Scherschun L, Cohen LV. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. *Plast Reconstr Surg*. Aug 2003; 112(2): 584-8. PMID 12900618
75. Baldursson BT, Kjartansson H, Konráðsdóttir F, et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. *Int J Low Extrem Wounds*. Mar 2015; 14(1): 37-43. PMID 25759413
76. Still J, Glat P, Silverstein P, et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. *Burns*. Dec 2003; 29(8): 837-41. PMID 14636761
77. Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis[®] wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. *J Tissue Viability*. Feb 2019; 28(1): 21-26. PMID 30509850
78. Gurtner GC, Garcia AD, Bakewell K, et al. A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone. *Int Wound J*. Feb 2020; 17(1): 55-64. PMID 31729833
79. Thomson SE, Ng NY, Riehle MO, et al. Bioengineered nerve conduits and wraps for peripheral nerve repair of the upper limb. *Cochrane Database Syst Rev*. Dec 07 2022; 12(12): CD012574. PMID 36477774
80. Lazic T, Falanga V. Bioengineered skin constructs and their use in wound healing. *Plast Reconstr Surg*. Jan 2011; 127 Suppl 1: 75S-90S. PMID 21200276
81. Saffle JR. Closure of the excised burn wound: temporary skin substitutes. *Clin Plast Surg*. Oct 2009; 36(4): 627-41. PMID 19793557
82. National Institute for Health and Care Excellence (NICE). Diabetic Foot Problems: Prevention and Management [NG19]. 2023; <https://www.nice.org.uk/guidance/ng19>.
83. Peirce SC, Carolan-Rees G. ReCell[®] Spray-On Skin System for Treating Skin Loss, Scarring and Depigmentation after Burn Injury: A NICE Medical Technology Guidance. *Appl Health Econ Health Policy*. Apr 2019; 17(2): 131-141. PMID 30635844
84. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Porcine Skin and Gradient Pressure Dressings (270.5). n.d.; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=139&ncdver=1&bc=AgAAQAAAAAAAA&>.

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

85. Centers for Medicare & Medicaid Services (CMS). Fact Sheet: CMS finalizes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019 <https://www.cms.gov/newsroom/fact-sheets/cms-finalizes-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center>.
86. Centers for Medicare & Medicaid Services. 2022. Fact Sheet. Calendar Year (CY) 2023 Medicare Physician Fee Schedule Final Rule. <https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2023-medicare-physician-fee-schedule-final-rule>.
87. ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210978/pdf/ohtas-21-1.pdf>
88. A prospective, randomized, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Charles M Zelen et al. International Wound Journal ISSN1742-4801. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949710/pdf/IWJ-14-307.pdf>
89. [PDF File generated from TMP3900.tif \(fda.gov\)](#)
90. U.S. Food and Drug Administration. (2001). Summary of safety and effectiveness data (P000036): DERMAGRAFT®. https://www.accessdata.fda.gov/cdrh_docs/pdf/P000036B.pdf
91. Integra® Omnigraft™ Dermal Regeneration Matrix - Smart Solutions for Serious Wounds. Patient Guide to Healing Diabetic Foot Ulcers@ [P900033S042c.pdf \(fda.gov\)](#)
92. [file:///C:/Users/e41724/Downloads/Clinical_and_Cost_Efficacy_of_Advanced_Wound_Care_.pdf](#)
93. Zelen CM, Orgill D, Serena T, Galiano R, Carter MJ, DiDomenico LA, Keller J, Kaufman J, Li WW. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J 2017; 14:307–315
94. ONT Health Technol Assess Ser 2021; 21(7): 1-165. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210978/pdf/ohtas-21-1.pdf>
95. ECRI Clinical Evidence Assessment. Kerecis Omega 3 (Kerecis LLC) for Treating Chronic Wounds. January 2025.

Policy History

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

- | | |
|------------|--|
| 09/07/2017 | Medical Policy Committee review |
| 09/20/2017 | Medical Policy Implementation Committee approval. New policy. |
| 05/03/2018 | Medical Policy Committee review |
| 05/16/2018 | Medical Policy Implementation Committee approval. DermACELL and FlexHD Pliable added to medically necessary statement on breast reconstructive surgery. Integra Flowable Wound Matrix added to medically necessary statement on use of Integra Dermal Regeneration Template for diabetic lower-extremity ulcers. Several products added to investigational list. |
| 01/01/2019 | Coding update |

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

05/02/2019	Medical Policy Committee review
05/15/2019	Medical Policy Implementation Committee approval. FlexiGraft removed from investigational statement. This note was added "This MP is not applicable to injection laryngoplasty for the treatment of vocal fold paralysis or paresis."
05/07/2020	Medical Policy Committee review
05/13/2020	Medical Policy Implementation Committee approval. No change to coverage.
05/06/2021	Medical Policy Committee review
05/12/2021	Medical Policy Implementation Committee approval. New investigational indications added.
01/07/2022	Coding Update
02/03/2022	Medical Policy Committee review
02/09/2022	Medical Policy Implementation Committee approval. MatriStem Surgical Matrix rebranded to Gentrix Surgical Matrix.
03/20/2022	Coding update
6/08/2022	Medical Policy Implementation Committee approval. AxoGuard Nerve Protector (AxoGen) removed from investigation list.
09/20/2022	Coding Update
09/28/2022	Coding Update
12/21/2022	Coding Update
01/05/2023	Medical Policy Committee review
01/11/2023	Medical Policy Implementation Committee approval. Time frames added for eligible products.
03/20/2023	Coding update
07/06/2023	Medical Policy Committee review
07/12/2023	Medical Policy Implementation Committee approval. Added ReCell as investigational. Removed PriMatrix and PriMatrix Dermal Repair Scaffold from investigational list and made PriMatrix eligible for diabetic foot ulcers with criteria.
09/20/2023	Coding update
09/27/2023	Added InnovaBurn ^{®†} , InnovaMatrix ^{®†} , InnovaMatrix ^{®†} XL, Miro3D, Resolve Matrix ^{™†} , and Wound Matrix ^{™†} to the list of all other skin and soft tissue substitutes that are investigational and not listed in the eligible for coverage section.
03/27/2024	Coding update
05/02/2024	Medical Policy Committee review
05/08/2024	Medical Policy Implementation Committee approval. mVASC and TheraSkin added to eligible for coverage statement for diabetic lower-extremity ulcers. Several products added to investigational list. Coding update.
10/01/2024	Coding update. Micromatrix flex and Mirotract wound matrix sheet was added to the list of investigational products.
01/01/2025	Coding update. RECELL System was added to the skin and soft tissue substitutes list as investigational.
02/20/2025	Coding update
03/25/2025	Coding update
05/01/2025	Medical Policy Committee review

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

05/13/2025 Medical Policy Implementation Committee approval. Kerecis®‡ Omega3 was added as eligible for coverage. Investigational list updated. AxoGuard Nerve Protector (AxoGen) was added back to investigational list.

10/01/2025 Coding update, investigational list updated.

01/01/2026 Coding update

04/01/2026 Coding update

06/04/2026 Medical Policy Committee review

06/10/2026 Medical Policy Implementation Committee review

08/20/2026 Medical Quality Management Committee approval. The following statement was changed from investigational to not medically necessary: “The use of bioengineered skin and soft tissue substitutes when patient selection criteria are not met is considered to be not medically necessary.”

10/01/2026 Coding update, investigational list updated.

Next Scheduled Review Date: 06/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	1044T, 1045T, 1046T, 1047T, 1048T, 1049T, 15011, 15012, 15013, 15014, 15015, 15016, 15017, 15018, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15777
HCPCS	A2002, A2004, A2005, A2006, A2007, A2008, A2009, A2010, A2011, A2012, A2013, A2014, A2015, A2016, A2017, A2018, A2019, A2020, A2021, A2022, A2023, A2024, A2025, A2026, A2027, A2028, A2029, A2030, A2031, A2032, A2033, A2034, A2036, A2037, A2038, A2039, A2041, A2042, A2043, A2044, A2045, A4100, A6460, A6461, C1832, C9353, C9354, C9356, C9358, C9360, C9361, C9363, C9364, C9399, Q4101, Q4102, Q4103, Q4104, Q4105, Q4107, Q4108, Q4110, Q4111, Q4112, Q4113, Q4114, Q4115, Q4116, Q4117, Q4118, Q4121, Q4122, Q4123, Q4124, Q4125, Q4126, Q4127, Q4128, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143, Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166, Q4167, Q4175, Q4179, Q4182, Q4193, Q4195, Q4196, Q4197, Q4200, Q4202, Q4203, Q4220, Q4222, Q4226, Q4238, Q4431, Q4432, Q4433 Delete codes effective 10/01/2025: Q4169, Q4255 Delete code effective 01/01/2026: Q4100, Q4106 Add codes effective 10/01/2026: A2046, A2047, A2048, A2050
ICD-10 Diagnosis	All Related Diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

Bioengineered Skin and Soft Tissue Substitutes

Policy # 00572

Original Effective Date: 12/01/2017

Current Effective Date: 07/01/2026

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.